A Study of AC682 In Chinese Patients With ER+/HER2- Locally Advanced or Metastatic Breast Cancer

Summary

This clinical trial is evaluating AC682 in participants with estrogen receptor positive/human epidermal growth factor 2 negative (ER+/HER2-) locally advanced or metastatic breast cancer. The main goals of this study are to: 1. To evaluate the safety and tolerability of AC682 2. To evaluate the pharmacokinetic of AC682 3. To evaluate the preliminary anti-tumor activity of AC682

Timeline

Start

2022-10-01

Primary completion

2023-09-28

Completion

2023-09-28

Outcome

Outcome not reported

Stopped (Business): “Voluntarily terminate the study since the sponsor's development strategy was adjusted.”

Drugs

Indications